Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
Saurabh Zanwar(Mayo Clinic), Shaji Kumar(Mayo Clinic), David Dingli, Francis K. Buadi, Dragan Jevremović(Mayo Clinic in Arizona), Robert A. Kyle(Mayo Clinic), Horatiu Olteanu(Mayo Clinic in Arizona), Prashant Kapoor, Nadine Abdallah(Mayo Clinic), Amie Fonder, Moritz Binder(Mayo Clinic in Arizona), Yi L. Hwa, Rahma Warsame, Joselle Cook(Mayo Clinic), Gregory E. Otteson(Mayo Clinic in Arizona), Pedro Horna(Mayo Clinic), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Eli Muchtar(Mayo Clinic), Yi Lin, Michelle Rogers(Mayo Clinic in Arizona), Nelson Leung(Mayo Clinic in Arizona), Morie A. Gertz(Mayo Clinic in Arizona), Miriam Hobbs, Angela Dispenzieri(Mayo Clinic), Suzanne Hayman(Mayo Clinic in Arizona), Abiola Bolarinwa(Mayo Clinic in Arizona)
Cited by 8
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k